BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

143 related articles for article (PubMed ID: 38741943)

  • 1. Clinical Characteristics, Prognosis and Treatment of Bloodstream Infections with
    Liu Y; Li F; Fang Y; Zhong Q; Xiao Y; Zheng Y; Zhu J; Zhao C; Cao X; Xiong J; Hu L
    Infect Drug Resist; 2024; 17():1811-1825. PubMed ID: 38741943
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A Retrospective Analysis of Risk Factors and Patient Outcomes of Bloodstream Infection with Extended-Spectrum β-Lactamase-Producing
    Xiao Y; Hang Y; Chen Y; Fang X; Cao X; Hu X; Luo H; Zhu H; Zhu W; Zhong Q; Hu L
    Infect Drug Resist; 2020; 13():4289-4296. PubMed ID: 33262623
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparison of therapy with β-lactam/β-lactamase inhibitor combinations or carbapenems for bacteraemia of nonurinary source caused by ESBL-producing Escherichia coli or Klebsiella pneumoniae.
    Luo H; Xiao Y; Hang Y; Chen Y; Zhu H; Fang X; Cao X; Zou S; Hu X; Xiong J; Zhong Q; Hu L
    Ann Clin Microbiol Antimicrob; 2021 Sep; 20(1):63. PubMed ID: 34488786
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Risk factors and outcomes in non-transplant patients with extended-spectrum beta-lactamase-producing
    Xiao T; Yang K; Zhou Y; Zhang S; Ji J; Ying C; Shen P; Xiao Y
    Antimicrob Resist Infect Control; 2019; 8():144. PubMed ID: 31467670
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparison Between Carbapenems and β-Lactam/β-Lactamase Inhibitors in the Treatment for Bloodstream Infections Caused by Extended-Spectrum β-Lactamase-Producing
    Muhammed M; Flokas ME; Detsis M; Alevizakos M; Mylonakis E
    Open Forum Infect Dis; 2017; 4(2):ofx099. PubMed ID: 28702469
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Risk factors and outcome of extended-spectrum β-lactamase-producing Enterobacter cloacae bloodstream infections.
    Qureshi ZA; Paterson DL; Pakstis DL; Adams-Haduch JM; Sandkovsky G; Sordillo E; Polsky B; Peleg AY; Bhussar MK; Doi Y
    Int J Antimicrob Agents; 2011 Jan; 37(1):26-32. PubMed ID: 21075605
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clinical efficacy of β-lactam/β-lactamase inhibitor combinations for the treatment of bloodstream infection due to extended-spectrum β-lactamase-producing Enterobacteriaceae in haematological patients with neutropaenia: a study protocol for a retrospective observational study (BICAR).
    Gudiol C; Royo-Cebrecos C; Tebe C; Abdala E; Akova M; Álvarez R; Maestro-de la Calle G; Cano A; Cervera C; Clemente WT; Martín-Dávila P; Freifeld A; Gómez L; Gottlieb T; Gurguí M; Herrera F; Manzur A; Maschmeyer G; Meije Y; Montejo M; Peghin M; Rodríguez-Baño J; Ruiz-Camps I; Sukiennik TC; Carratalà J;
    BMJ Open; 2017 Jan; 7(1):e013268. PubMed ID: 28115333
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Empiric Therapy With Carbapenem-Sparing Regimens for Bloodstream Infections due to Extended-Spectrum β-Lactamase-Producing Enterobacteriaceae: Results From the INCREMENT Cohort.
    Palacios-Baena ZR; Gutiérrez-Gutiérrez B; Calbo E; Almirante B; Viale P; Oliver A; Pintado V; Gasch O; Martínez-Martínez L; Pitout J; Akova M; Peña C; Molina Gil-Bermejo J; Hernández A; Venditti M; Prim N; Bou G; Tacconelli E; Tumbarello M; Hamprecht A; Giamarellou H; Almela M; Pérez F; Schwaber MJ; Bermejo J; Lowman W; Hsueh PR; Paño-Pardo JR; Torre-Cisneros J; Souli M; Bonomo RA; Carmeli Y; Paterson DL; Pascual Á; Rodríguez-Baño J;
    Clin Infect Dis; 2017 Oct; 65(10):1615-1623. PubMed ID: 29020250
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Risk factors for bloodstream infection caused by extended-spectrum β-lactamase-producing Escherichia coli and Klebsiella pneumoniae: A focus on antimicrobials including cefepime.
    Chopra T; Marchaim D; Johnson PC; Chalana IK; Tamam Z; Mohammed M; Alkatib S; Tansek R; Chaudhry K; Zhao JJ; Pogue JM; Kaye KS
    Am J Infect Control; 2015 Jul; 43(7):719-23. PubMed ID: 25934068
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Risk factors for antibiotic resistance and mortality in patients with bloodstream infection of Escherichia coli.
    Zhao S; Wu Y; Dai Z; Chen Y; Zhou X; Zhao J
    Eur J Clin Microbiol Infect Dis; 2022 May; 41(5):713-721. PubMed ID: 35190911
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Bacteremia due to extended-spectrum-beta-lactamase-producing Enterobacter cloacae: role of carbapenem therapy.
    Lee CC; Lee NY; Yan JJ; Lee HC; Chen PL; Chang CM; Wu CJ; Ko NY; Wang LR; Chi CH; Ko WC
    Antimicrob Agents Chemother; 2010 Sep; 54(9):3551-6. PubMed ID: 20547798
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Mortality, hospital length of stay, and recurrent bloodstream infections associated with extended-spectrum beta-lactamase-producing Escherichia coli in a low prevalence region: A 20-year population-based large cohort study.
    Ling W; Paterson DL; Harris PNA; Furuya-Kanamori L; Edwards F; Laupland KB
    Int J Infect Dis; 2024 Jan; 138():84-90. PubMed ID: 37949363
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Newly Named Klebsiella aerogenes (formerly Enterobacter aerogenes) Is Associated with Poor Clinical Outcomes Relative to Other
    Wesevich A; Sutton G; Ruffin F; Park LP; Fouts DE; Fowler VG; Thaden JT
    J Clin Microbiol; 2020 Aug; 58(9):. PubMed ID: 32493786
    [No Abstract]   [Full Text] [Related]  

  • 14. A retrospective analysis of risk factors and outcomes in patients with extended-spectrum beta-lactamase-producing Escherichia coli bloodstream infections.
    Xiao T; Wu Z; Shi Q; Zhang X; Zhou Y; Yu X; Xiao Y
    J Glob Antimicrob Resist; 2019 Jun; 17():147-156. PubMed ID: 30634054
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A Multinational, Preregistered Cohort Study of β-Lactam/β-Lactamase Inhibitor Combinations for Treatment of Bloodstream Infections Due to Extended-Spectrum-β-Lactamase-Producing Enterobacteriaceae.
    Gutiérrez-Gutiérrez B; Pérez-Galera S; Salamanca E; de Cueto M; Calbo E; Almirante B; Viale P; Oliver A; Pintado V; Gasch O; Martínez-Martínez L; Pitout J; Akova M; Peña C; Molina J; Hernández A; Venditti M; Prim N; Origüen J; Bou G; Tacconelli E; Tumbarello M; Hamprecht A; Giamarellou H; Almela M; Pérez F; Schwaber MJ; Bermejo J; Lowman W; Hsueh PR; Mora-Rillo M; Natera C; Souli M; Bonomo RA; Carmeli Y; Paterson DL; Pascual A; Rodríguez-Baño J
    Antimicrob Agents Chemother; 2016 Jul; 60(7):4159-69. PubMed ID: 27139473
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Epidemiology and Burden of Bloodstream Infections Caused by Extended-Spectrum Beta-Lactamase Producing Enterobacteriaceae in a Pediatric Hospital in Senegal.
    Ndir A; Diop A; Faye PM; Cissé MF; Ndoye B; Astagneau P
    PLoS One; 2016; 11(2):e0143729. PubMed ID: 26867226
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparison of Predictors and Mortality Between Bloodstream Infections Caused by ESBL-Producing Escherichia coli and ESBL-Producing Klebsiella pneumoniae.
    Scheuerman O; Schechner V; Carmeli Y; Gutiérrez-Gutiérrez B; Calbo E; Almirante B; Viale PL; Oliver A; Ruiz-Garbajosa P; Gasch O; Gozalo M; Pitout J; Akova M; Peña C; Molina J; Hernández-Torres A; Venditti M; Prim N; Origüen J; Bou G; Tacconelli E; Tumbarello M; Hamprecht A; Karaiskos I; de la Calle C; Pérez F; Schwaber MJ; Bermejo J; Lowman W; Hsueh PR; Navarro-San Francisco C; Bonomo RA; Paterson DL; Pascual A; Rodríguez-Baño J;
    Infect Control Hosp Epidemiol; 2018 Jun; 39(6):660-667. PubMed ID: 29618394
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Role of empirical and targeted therapy in hospitalized patients with bloodstream infections caused by ESBL-producing Enterobacteriaceae.
    Falcone M; Vena A; Mezzatesta ML; Gona F; Caio C; Goldoni P; Trancassini AM; Conti C; Orsi GB; Carfagna P; Stefani S; Venditti M
    Ann Ig; 2014; 26(4):293-304. PubMed ID: 25001119
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Predictors of outcome in patients with severe sepsis or septic shock due to extended-spectrum β-lactamase-producing Enterobacteriaceae.
    Russo A; Falcone M; Gutiérrez-Gutiérrez B; Calbo E; Almirante B; Viale PL; Oliver A; Ruiz-Garbajosa P; Gasch O; Gozalo M; Pitout J; Akova M; Peña C; Cisneros JM; Hernández-Torres A; Farcomeni A; Prim N; Origüen J; Bou G; Tacconelli E; Tumbarello M; Hamprecht A; Karaiskos I; de la Calle C; Pérez F; Schwaber MJ; Bermejo J; Lowman W; Hsueh PR; Mora-Rillo M; Rodriguez-Gomez J; Souli M; Bonomo RA; Paterson DL; Carmeli Y; Pascual A; Rodríguez-Baño J; Venditti M;
    Int J Antimicrob Agents; 2018 Nov; 52(5):577-585. PubMed ID: 29969692
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Efficacy of β-lactam/β-lactamase inhibitors to treat extended-spectrum beta-lactamase-producing Enterobacterales bacteremia secondary to urinary tract infection in kidney transplant recipients (INCREMENT-SOT Project).
    Pierrotti LC; Pérez-Nadales E; Fernández-Ruiz M; Gutiérrez-Gutiérrez B; Tan BH; Carratalà J; Oriol I; Paul M; Cohen-Sinai N; López-Medrano F; San-Juan R; Montejo M; Freire MP; Cordero E; David MD; Merino E; Mehta Steinke S; Grossi PA; Cano Á; Seminari EM; Valerio M; Gunseren F; Rana M; Mularoni A; Martín-Dávila P; van Delden C; Hamiyet Demirkaya M; Koçak Tufan Z; Loeches B; Iyer RN; Soldani F; Eriksson BM; Pilmis B; Rizzi M; Coussement J; Clemente WT; Roilides E; Pascual Á; Martínez-Martínez L; Rodríguez-Baño J; Torre-Cisneros J; Aguado JM;
    Transpl Infect Dis; 2021 Jun; 23(3):e13520. PubMed ID: 33222379
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.